Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 173Leukemia, Myeloid, Acute 152Breast Neoplasms 146Neoplasms 143Neoplasm Metastasis 142Colorectal Neoplasms 137Recurrence 105Ovarian Neoplasms 101Pancreatic Neoplasms 83Advanced Solid Tumor 82Lung Neoplasms 81Multiple Myeloma 77Prostatic Neoplasms 75Advanced Solid Tumors 74Stomach Neoplasms 73Squamous Cell Carcinoma of Head and Neck 72Carcinoma, Hepatocellular 68Glioblastoma 65Melanoma 64Lymphoma, Non-Hodgkin 64Triple Negative Breast Neoplasms 59Lymphoma, B-Cell 55Endometrial Neoplasms 54Myelodysplastic Syndromes 53Precursor Cell Lymphoblastic Leukemia-Lymphoma 52Lymphoma 52Glioma 51Brain Neoplasms 46Carcinoma, Renal Cell 44Hematologic Neoplasms 43

Interventions

venetoclax 1quizartinib 1Daunorubicin 1Cytarabine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × Sarcoma, Myeloid × Clear all
NCT05735184 2026-03-13

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Kura Oncology, Inc.

Phase 1 Recruiting
420 enrolled
Other hematologic neoplasmSarcoma

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡